The FDA has granted accelerated approval to the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (Yescarta, Kite Pharma) for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
“Once a follicular lymphoma patient’s disease relapses, the duration of response to care shortens with each round of therapy,” noted Caron A. Jacobson, MD, an assistant professor of medicine at Harvard Medical